Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost

31 Jul 2018
News

Malcolm Spicer @TheTanSheet malcolm.spicer@informa.com

Executive Summary

French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Sales & Earnings Consumer Emerging Markets

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS123602

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS123602

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost

News

Executive Summary

Related Content

Sanofi Lawsuit Delays OTC Nasacort Generic Competition

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert